Regulatory approval

Published by the Health Canada. Approved

ADCETRIS is indicated for the treatment of previously untreated adult patients with systemic anaplastic large cell lymphoma (sALCL), peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS) or angioimmunoblastic T-cell lymphoma (AITL), whose tumours express CD30, in combination with cyclophosphamide, doxorubicin, and prednisone (CHP).

This is written in the approval document.

Citation

Seagen Inc. Adcetris (brentuximab vedotin) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080158.PDF. Published April 2025. Accessed June 2025.

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Organizations	Biomarkers	Cancer types	Therapies
HC (1)	CD30 +	Anaplastic Large Cell Lymphoma	Brentuximab vedotin, Cyclophosphamide, Doxorubicin, Prednisone
HC (1)	CD30 +	Angioimmunoblastic T-Cell Lymphoma	Brentuximab vedotin, Cyclophosphamide, Doxorubicin, Prednisone
HC (1)	CD30 +	Peripheral T-Cell lymphoma, NOS	Brentuximab vedotin, Cyclophosphamide, Doxorubicin, Prednisone

Contributions

Date	Contributor	Description
2024-10-30	Van Allen lab	Initial access of FDA approvals